Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
XEVUDY Inf Konz 500 mg/8ml Durchstf 8 ml
Drug
Xevudy, Konzentrat zur Herstellung einer Infusionslösung
Behandlung von COVID-19
08.03.0. – antivirals
HAM – Human medicine
KOINF – Concentrate for solution for infusion
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
D – no longer approved
1/14/2022
11/13/2025
Dosage strength
Xevudy, Konzentrat zur Herstellung einer Infusionslösung
Behandlung von COVID-19
01
D – no longer approved
11/13/2025
Package
7680684710018
Out of trade (1/14/2022 - 8/29/2024)
NA – No longer authorised
1 vial(s)
001
D – no longer approved
11/13/2025
Declaration
Component
500 mg sotrovimabum
histidinum
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
methioninum
aqua ad iniectabile
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
methioninum
aqua ad iniectabile
Authorisation holder
7601001000674
GlaxoSmithKline AG
Neuhofstrasse 4
6340 Baar (ZG)
Neuhofstrasse 4
6340 Baar (ZG)
Date of revision of the text
1/1/2026
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.